Literature DB >> 24068526

C3 nephritic factor associated with C3 glomerulopathy in children.

Camille Nicolas1, Vincent Vuiblet, Veronique Baudouin, Marie-Alice Macher, Isabele Vrillon, Nathalie Biebuyck-Gouge, Maud Dehennault, Sophie Gié, Denis Morin, Hubert Nivet, François Nobili, Tim Ulinski, Bruno Ranchin, Maria Chiarra Marinozzi, Stéphanie Ngo, Véronique Frémeaux-Bacchi, Christine Pietrement.   

Abstract

BACKGROUND: C3 glomerulopathy (C3G) is characterized by predominant C3 deposits in glomeruli and dysregulation of the alternative pathway of complement. Half of C3G patients have a C3 nephritic factor (C3NeF). C3G incorporated entities with a range of features on microscopy including dense deposit diseases (DDD) and C3 glomerulonephritis (C3GN). The aim of this work was to study children cases of C3G associated with C3NeF.
METHODS: We reviewed 18 cases of C3G with a childhood onset associated with C3NeF without identified mutations in CFH, CFI, and MCP genes.
RESULTS: Clinical histories started with recurrent hematuria for seven patients, nephrotic syndrome for four, acute post-infectious glomerulonephritis for three and acute renal failure for four. Twelve patients had a low C3 at first investigation. Kidney biopsy showed ten C3GN and eight DDD. Twenty-three percent of the patients tested presented elevated sC5b9. Seven patients relapsed 3 to 6 years after the onset. At the end of follow-up, two patients were under dialysis, 11 had a persistent proteinuria, five had none; four patients did not follow any treatment. Steroids were first used in 80 % of cases.
CONCLUSIONS: C3NeF associated C3G has a heterogeneous presentation and outcome. Anti-proteinuric agents may control the disease during follow-up, even after nephrotic syndrome at the onset. The efficiency of immunosuppressive therapy remains questionable.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24068526     DOI: 10.1007/s00467-013-2605-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  42 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

Review 2.  Alternative complement pathway assessment in patients with atypical HUS.

Authors:  Lubka T Roumenina; Chantal Loirat; Marie-Agnes Dragon-Durey; Lise Halbwachs-Mecarelli; Catherine Sautes-Fridman; Veronique Fremeaux-Bacchi
Journal:  J Immunol Methods       Date:  2011-01-06       Impact factor: 2.303

3.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

4.  Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  B A Warady; D Hébert; E K Sullivan; S R Alexander; A Tejani
Journal:  Pediatr Nephrol       Date:  1997-02       Impact factor: 3.714

5.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

Review 6.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

Review 7.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

8.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

9.  Immunosuppressive treatment of membranoproliferative glomerulonephritis.

Authors:  R Faedda; A Satta; F Tanda; M Pirisi; E Bartoli
Journal:  Nephron       Date:  1994       Impact factor: 2.847

10.  Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.

Authors:  Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Nicole C Meyer; Nicolò Borsa; Samih H Nasr; Richard J H Smith
Journal:  Kidney Int       Date:  2012-12-12       Impact factor: 10.612

View more
  16 in total

Review 1.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

2.  C4d as a Diagnostic Tool in Proliferative GN.

Authors:  Sanjeev Sethi; Samih H Nasr; An S De Vriese; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-05-19       Impact factor: 10.121

3.  A case of C3 glomerulonephritis successfully treated with eculizumab.

Authors:  Alexis Payette; Natalie Patey; Marie-Agnès Dragon-Durey; Véronique Frémeaux-Bacchi; Françoise Le Deist; Anne-Laure Lapeyraque
Journal:  Pediatr Nephrol       Date:  2015-03-22       Impact factor: 3.714

4.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

5.  C3 glomerulopathy and eculizumab: a report on four paediatric cases.

Authors:  Célia Lebreton; Justine Bacchetta; Frédérique Dijoud; Lucie Bessenay; Véronique Fremeaux-Bacchi; Anne Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2017-02-24       Impact factor: 3.714

Review 6.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

7.  Predictive factors for poor outcome in pediatric C3 glomerulonephritis.

Authors:  Mamiko Hosoya; Yukihiko Kawasaki; Ryo Maeda; Masatoki Sato; Kazuhide Suyama; Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2018-10-27

8.  Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report.

Authors:  Ana Pinho; Graça Ferreira; Conceição Mota
Journal:  BMC Res Notes       Date:  2014-11-07

9.  Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy.

Authors:  Mazdak A Khalighi; Shihtien Wang; Kammi J Henriksen; Margret Bock; Mahima Keswani; Shane M Meehan; Anthony Chang
Journal:  Clin Kidney J       Date:  2016-05-17

Review 10.  Overview of C3 Glomerulopathy.

Authors:  Vimal Master Sankar Raj; Roberto Gordillo; Deepa H Chand
Journal:  Front Pediatr       Date:  2016-05-06       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.